Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27607584 | 0.89 | MAOA (0.49) | MAOAMAOBCA1CA2CA4 | |
| SCHEMBL30753727 | 0.87 | MAOA (0.58) | MAOAMAOBCA1CA2CA4 | |
| SCHEMBL17364189 | 0.83 | MAOA (0.55) | MAOAMAOBCA1CA2CA4 | |
| SCHEMBL235913 | 0.82 | MAOA (0.58) | MAOAMAOBCA1CA2CA4 | |
| SCHEMBL38662707 | 0.80 | MAOA (0.51) | MAOAMAOBCA1CA2CA4 | |
| SCHEMBL31299574 | 0.80 | MAOA (0.56) | MAOAMAOBCA1CA2CA4 | |
| SCHEMBL1368207 | 0.80 | MAOA (0.56) | MAOAMAOBCA1CA2CA4 | |
| SCHEMBL238114 | 0.80 | MAOA (0.51) | MAOAMAOBCA1CA2CA4 | |
| SCHEMBL11542417 | 0.80 | MAOA (0.51) | MAOAMAOBCA1CA2CA4 | |
| SCHEMBL2550222 | 0.78 | MAOA (0.50) | MAOAMAOBCA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| US-11623921-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-11 | — | — | US | disclosed |
| CN-110511209-B | Indole carboxamide compounds useful as kinase inhibitors | 百时美施贵宝公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-15 | — | — | US | disclosed |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-15 | — | — | US | disclosed |
| US-20200165222-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200165222-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| EP-3209656-B1 | INDOLE CARBOXAMIDES COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-01 | — | — | EP | disclosed |
| EP-3209656-A1 | INDOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9688629-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688629-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688629-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-28 | — | — | US | disclosed |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-28 | — | — | US | disclosed |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | MAOA 791/4885MAOB 643/4885CA1 1518/4885 |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | MAOA 791/4885MAOB 643/4885CA1 1518/4885 |
| US-11623921-B2 | Indole carboxamide compounds | BTK, JAK2, BRD4 | MAOA 791/4885MAOB 643/4885CA1 1518/4885 |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | MAOA 791/4885MAOB 643/4885CA1 1518/4885 |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | MAOA 791/4885MAOB 643/4885CA1 1518/4885 |
| US-20200165222-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | MAOA 791/4885MAOB 643/4885CA1 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.